These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 21700430

  • 21. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW.
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [Abstract] [Full Text] [Related]

  • 22. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed S, Stauffer VL.
    Schizophr Res; 2004 Jun 01; 68(2-3):331-7. PubMed ID: 15099614
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A, Cucchiaro J, Silva R, Mao Y, Xu J, Pikalov A, Marder SR.
    Eur Psychiatry; 2015 Jan 01; 30(1):26-31. PubMed ID: 25280429
    [Abstract] [Full Text] [Related]

  • 24. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
    Mosolov SN, Malyutin AV, Pikalov AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019 Jan 01; 119(12):29-37. PubMed ID: 31994511
    [Abstract] [Full Text] [Related]

  • 25. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May 01; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 26. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.
    Neuropsychopharmacology; 2015 Dec 01; 40(13):3053-60. PubMed ID: 26089183
    [Abstract] [Full Text] [Related]

  • 27. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec 01; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 28. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar 01; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R.
    Neuropsychopharmacology; 2008 May 01; 33(6):1217-28. PubMed ID: 17625502
    [Abstract] [Full Text] [Related]

  • 30. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM, Bossie CA, Turkoz I, Alphs L.
    Schizophr Res; 2009 Aug 01; 113(1):56-64. PubMed ID: 19560322
    [Abstract] [Full Text] [Related]

  • 31. Iloperidone: in schizophrenia.
    Scott LJ.
    CNS Drugs; 2009 Oct 01; 23(10):867-80. PubMed ID: 19739696
    [Abstract] [Full Text] [Related]

  • 32. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
    Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC.
    Schizophr Res; 2004 May 01; 68(1):11-9. PubMed ID: 15037335
    [Abstract] [Full Text] [Related]

  • 33. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM, Yang R, Youakim JM.
    Schizophr Res; 2012 Mar 01; 135(1-3):116-22. PubMed ID: 22178084
    [Abstract] [Full Text] [Related]

  • 34. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
    Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM.
    J Psychiatr Res; 2014 Jun 01; 53():14-22. PubMed ID: 24613032
    [Abstract] [Full Text] [Related]

  • 35. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.
    Schizophr Res; 2014 Feb 01; 152(2-3):450-7. PubMed ID: 24412468
    [Abstract] [Full Text] [Related]

  • 36. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
    Khan A, Yavorsky WC, Liechti S, DiClemente G, Rothman B, Opler M, DeFries A, Jovic S.
    J Clin Psychopharmacol; 2013 Feb 01; 33(1):109-17. PubMed ID: 23277234
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF.
    Curr Med Res Opin; 2004 Sep 01; 20(9):1357-63. PubMed ID: 15383183
    [Abstract] [Full Text] [Related]

  • 38. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
    Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, Loebel A.
    J Psychiatr Res; 2013 May 01; 47(5):670-7. PubMed ID: 23421963
    [Abstract] [Full Text] [Related]

  • 39. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.
    Schizophr Res; 2010 Feb 01; 116(2-3):107-17. PubMed ID: 19959339
    [Abstract] [Full Text] [Related]

  • 40. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
    Weiden PJ, Manning R, Wolfgang CD, Ryan JM, Mancione L, Han G, Ahmed S, Mayo MG.
    CNS Drugs; 2016 Aug 01; 30(8):735-47. PubMed ID: 27379654
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.